Kolorektales Karzinom: Erfolg von Cetuximab nur bei Karzinom ohne K-ras-Mutation

Literatur

• 1 Amado R G. et al . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.  J Clin Oncol. 2008;  26 1626-1634
• 2 Van Cutsem E. et al . KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience.  J Clin Oncol. 2008;  26 2
• 3 Bokemeyer C. et al . KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience.  J Clin Oncol. 2008;  26 Abstract 4000
• 4 Di Nicolantonio F. et al . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.  J Clin Oncol. 2008;  26 5705-5712